| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,408,218 | -3,679,090 |
| Accrued interest | 9,268 | 6,107 |
| Change in fair value of liability classified warrants | 10,061 | 9,063 |
| Consultant compensation | 253,731 | 203,014 |
| Amortization of orginal issue discount and debt issuance costs | - | 0 |
| Stock-based compensation | 152,747 | 106,889 |
| Unbilled receivable | -119,704 | 1,080,864 |
| Prepaid expenses and other assets | -780,894 | -1,185 |
| Accounts payable | -893,621 | -314,247 |
| Accrued expenses and other liabilities | 715,097 | 351,789 |
| Net cash used in operating activities | -6,280,459 | -4,414,280 |
| Investment in property and equipment | 123,643 | - |
| Net cash used in investing activities | -123,643 | - |
| Repayment of convertible notes | - | 0 |
| Proceeds from public offerings | 1,100,007 | 1,100,007 |
| Proceeds from warrant exercises | 1,887,709 | 390,855 |
| Proceeds from warrant inducement, net of issuance costs | 2,200,012 | 2,200,012 |
| Transaction costs from public offerings | 204,193 | 204,193 |
| Transaction costs associated with warrant inducements | 297,021 | 291,611 |
| Repayment of financed insurance premiums | 111,271 | 71,292 |
| Net cash provided by financing activities | 4,575,243 | 3,123,778 |
| Increase (decrease) in cash and cash equivalents | -1,828,859 | -1,290,502 |
| Cash and cash equivalents at beginning of period | 3,502,077 | - |
| Cash and cash equivalents at end of period | 1,673,218 | - |
Ensysce Biosciences, Inc. (ENSCW)
Ensysce Biosciences, Inc. (ENSCW)